NPI 1043323058: Open Payments
NPI 1043323058. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$470 in 24 payments from 8 companies in 2025. Trend: 2023 $41 · 2024 $325 · 2025 $470
Food & beverage: $470
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $102 |
| Janssen Pharmaceuticals, Inc | 4 | $85 |
| Indivior Inc. | 3 | $72 |
| Axsome Therapeutics, Inc. | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Braeburn Inc. | 2 | $45 |
| ABBVIE INC. | 2 | $37 |
| Lundbeck LLC | 1 | $17 |
Products named: CAPLYTA, SPRAVATO, SUBLOCADE, REXULTI, Auvelity, BRIXADI, VRAYLAR.
